Membrane Perturbations and Assay Interferences by Ivermectin Explain Its In Vitro SARS-CoV‑2 Antiviral Activities and Lack of Translatability

The antiparasitic drug ivermectin was proposed as a repurposed drug for the treatment of SARS-CoV-2 infection based on in vitro studies, but proved ineffective in high-quality clinical trials. When exploring possible reasons for this disconnect, we found that ivermectin interferes with AlphaScreen a...

全面介紹

Saved in:

書目詳細資料
主要作者:	Richard T. Eastman (6051881) (author)
其他作者:	Radda Rusinova (4870042) (author), Karl F. Herold (605487) (author), Xi-Ping Huang (391870) (author), Ty Voss (12046550) (author), Alex D. White (7356104) (author), Hugh C. Hemmings (1330833) (author), Olaf S. Andersen (823886) (author), Jayme L. Dahlin (486120) (author)
出版:	2025
主題:	Biochemistry Medicine Pharmacology Biotechnology Cancer Infectious Diseases Virology Computational Biology Chemical Sciences not elsewhere classified Information Systems not elsewhere classified quality clinical trials perturbing bioactivity early low nanomolar concentrations low micromolar concentrations highlight lessons learned exploring possible reasons 2 viral burden 2 infection based safe antiparasitic drug antiparasitic drug ivermectin ivermectin reduced sars effective antiviral agent antiviral agent repurposed drug drug development pursuing ivermectin ivermectin interferes ivermectin explain proved ineffective perspective </ original justifications membrane perturbations level rationale identifying membrane becomes cytotoxic assay interferences alphascreen assays
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!

Membrane Perturbations and Assay Interferences by Ivermectin Explain Its In Vitro SARS-CoV‑2 Antiviral Activities and Lack of Translatability

相似書籍